Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 6Thoracic 1Endocrine 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Paclitaxel 4fosbretabulin 3Radiotherapy 3selpercatinib 2Filgrastim 2Everolimus 2Doxorubicin 2Cisplatin 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1sargramostim 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1mercaptoundecahydrododecaborate 1gallium Ga 68 dotatate 1fostamatinib 1entrectinib 1combretastatin 1alectinib 1aldesleukin 1Triiodothyronine 1Thyrotropin Alfa 1Thyrotropin 1Thalidomide 1Tamoxifen 1Semaxinib 1Rosiglitazone 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Azacitidine × Endocrine × Clear all
NCT00004062 2013-12-19

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 1 Completed
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡